Skip to main content

Advertisement

Log in

Prognosis and mortality of polymyositis and dermatomyositis patients

  • Original Article
  • Published:
Clinical Rheumatology Aims and scope Submit manuscript

Abstract

The objective of this study was to assess the long-term outcome of polymyositis (PM) and dermatomyositis (DM) and the factors predictive of this outcome in a nationwide series in Finland. One hundred and seventy-six patients with PM and 72 patients with DM diagnosed in Finland in 1969–1985 were selected from the national hospital discharge register according to the diagnostic criteria of Bohan and Peter and followed up until death or till the end of August 1995. Gender, age, delay of therapy, serum creatine kinase, erythrocyte sedimentation rate, initial dose of corticosteroids and duration of cytostatic therapy were assessed as factors prognostic of death. The 5-year survival rate for PM was 75% [95% confidence interval (CI): 68–81%] and that for DM 63% (50–73%), and the respective 10-year survival rates were 55% (47–62%) and 53% (41–64%). The median survival for polymyositis was 11.0 years (95% CI: 9.5–13.3) and that for DM 12.3 years (5.5–20.7). The standardized mortality ratio for the combined group of PM and DM showed approximately threefold mortality compared to the general population. Compared to PM patients, the subjects with DM had a 1.47-fold (95% CI: 0.99–2.12) age- and sex-adjusted risk of mortality. Except for age in both groups and the delay in diagnosis in the PM group, no other individual factor reached significance as a predictor of death. However, cancer had a hazard ratio (HR) of 2.16 for death (95% CI: 0.95–4.50) in the DM group and 1.99 (95% CI: 1.01–3.94) in the PM group. A comparison of the causes of death in the PM and DM groups showed that the patients with DM had a greater risk of dying from cancer (age-adjusted HR 5.11, 95% CI: 2.31–11.3). According to this nationwide analysis of survival and its prognostic factors in patients with PM and DM, the latter group had an increased age-adjusted risk for mortality compared to the former. The difference seems to be mostly explained by the fact that the patients with DM had a higher risk of dying from cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Medsger TA Jr, Robinson H, Masi AT (1971) Factors affecting survivorship in polymyositis: a life-table study of 124 patients. Arthritis Rheum 14:249–258

    Article  PubMed  Google Scholar 

  2. Carpenter JR., Bunch TW, Engel AG, O’Brien PC (1977) Survival in polymyositis: corticosteroids and risk factors. J Rheumatol 4:207–214

    PubMed  CAS  Google Scholar 

  3. Henriksson KG, Sandstedt P (1982) Polymyositis—treatment and prognosis: a study of 107 patients. Acta Neurol Scand 65:280–300

    Article  PubMed  CAS  Google Scholar 

  4. Hochberg MC, Lopez-Acuna D, Gittelsohn AM (1983) Mortality from polymyositis and dermatomyositis in the United States, 1968–1978. Arthritis Rheum 26:1465–1471

    Article  PubMed  CAS  Google Scholar 

  5. Benbassat J, Gefel D, Larholt K, Sukenik S, Morgenstern V, Zlotnick A (1985) Prognostic factors in polymyositis/derma-tomyositis. A computer-assisted analysis of ninety-two cases. Arthritis Rheum 28:249–255

    Article  PubMed  CAS  Google Scholar 

  6. Maugars YM, Berthelot JM, Abbas AA, Mussini JM, Nguyen JM, Prost AM (1996): Long-term prognosis of 69 patients with dermatomyositis or polymyositis. Clin Exp Rheumatol 14:263–274

    PubMed  CAS  Google Scholar 

  7. Marie I, Hachulla E, Hatron P-Y, Hellot M-F, Levesque H, Devulder B, Courtois H (2001) Polymyositis and dermatomyositis: short term and long term outcome, and predictive factors of prognosis. J Rheumatol 28:2230–2237

    PubMed  CAS  Google Scholar 

  8. Bohan A, Peter JB, Bowman RL, Pearson CM (1977) Computer-assisted analysis of 153 patients with polymyositis and dermatomyositis. Medicine 56:255–286

    Article  PubMed  CAS  Google Scholar 

  9. Sigurgeirsson B, Lindelöf B, Edhag O, Allander EA (1992) Risk of cancer in patients with dermatomyositis or polymyositis. A population-based study. N Engl J Med 6:363–367

    Article  Google Scholar 

  10. Bohan A, Peter JB (1975) Polymyositis and dermatomyositis (first of two parts). N Engl J Med 292:344–347

    PubMed  CAS  Google Scholar 

  11. Bohan A, Peter JB (1975) Polymyositis and dermatomyositis (second of two parts). N Engl J Med 292:403–407

    PubMed  CAS  Google Scholar 

  12. Marie I, Hatron P-Y, Levesque H, Hachulla E, Hellot M-F, Michon-Pasturel U, Courtois H, Devulder B (1999) Influence of age on characteristics of polymyositis and dermatomyositis in adults. Medicine (Baltimore) 78:139–147

    Article  CAS  Google Scholar 

  13. Fudman EJ, Schnitzer TJ (1986) Dermatomyositis without creatine kinase elevation. A poor prognostic sign. Am J Med 80:329–332

    Article  PubMed  CAS  Google Scholar 

  14. Lakhanpal S, Bunch TW, Ilstrup DM, Melton LJ III (1986) Polymyositis-dermatomyositis and malignant lesions: does an association exist? Mayo Clin Proc 61:645–653

    PubMed  CAS  Google Scholar 

  15. Nicholls D (1987) Dermatomyositis without creatine kinase elevation. Am J Med 83:182–183

    Article  PubMed  CAS  Google Scholar 

  16. Basset-Seguin N, Roujeau JC, Gherardi R, Guillaume JC, Revuz J, Touraine R (1990) Prognostic factors and predictive signs of malignancy in adult dermatomyositis. Arch Dermatol 126:633–637

    Article  PubMed  CAS  Google Scholar 

  17. O’Leary PA, Waismann M (1940) Dermatomyositis: a study of 40 cases. Arch Dermatol Syphilol 41:1001–1019

    Google Scholar 

  18. Metzger AL, Bohan A, Goldberg LS, Bluestone R, Pearson CM (1974) Polymyositis and dermatomyositis: combined methotrexate and corticosteroid therapy. Ann Intern Med 81:182–189

    PubMed  CAS  Google Scholar 

  19. Bunch TW (1981) Prednisone and azathioprine for polymyositis: Long-term followup. Arthritis Rheum 24:45–48

    Article  PubMed  CAS  Google Scholar 

  20. Bong JJ, Lansdown M (2002) Figure. BMJ 324:1344

    Article  Google Scholar 

  21. Airio A, Pukkala E, Isomäki H (1995) Elevated cancer incidence in patients with dermatomyositis: a population based study. J Rheumatol 22:1300–1303

    PubMed  CAS  Google Scholar 

  22. Chow WH, Gridley G, Mellemkjaer L, McLauglin JK, Olsen JH, Fraumeni JF Jr (1995) Cancer risk following polymyositis and dermatomyositis: a nationwide cohort study in Denmark. Cancer Causes Control 6:9–13

    Article  PubMed  CAS  Google Scholar 

  23. Hill CL, Zhang Y, Sigurgeirsson B, Pukkala E, Mellemkjaer L, Airio A, Evans SR, Felson DT (2001) Frequency of specific cancer types in dermatomyositis and polymyositis: a population-based study. Lancet 357:96–100

    Article  PubMed  CAS  Google Scholar 

  24. Marie I, Hatron P-Y, Hachulla E, Wallaert B, Michon-Pasturel U, Devulder B (1998) Pulmonary involvement in polymyositis and in dermatomyositis. J Rheumatol 25:1336–1343

    PubMed  CAS  Google Scholar 

  25. Tymms KE, Webb J (1985) Dermatopolymyositis and other connective tissue diseases: areview of 105 cases. J Rheumatol 12:1140–1148

    PubMed  CAS  Google Scholar 

  26. Hernandez-Cruz B, Sifuentes-Osornio J, Ponce-de-Leon Ro-sales S, Ponce-de-Leon Garduno A, Diaz-Jouanen E (1999) Mycobacterium tuberculosis infection in patients with systemic rheumatic diseases. A case series. Clin Exp Rheumatol 17:289–296

    PubMed  CAS  Google Scholar 

  27. Haq I, Isenberg DA (2002) Myositis and swollen knees: disease or treatment complication? Ann Rheum Dis 61:544–546

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to A. Airio.

Additional information

Published online: 14 February 2006

Rights and permissions

Reprints and permissions

About this article

Cite this article

Airio, A., Kautiainen, H. & Hakala, M. Prognosis and mortality of polymyositis and dermatomyositis patients. Clin Rheumatol 25, 234–239 (2006). https://doi.org/10.1007/s10067-005-1164-z

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10067-005-1164-z

Keywords

Navigation